AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Posted: 29 May 2023 Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce new data showing the efficacy of its investigational FAK inhibitor, AMP945, in a preclinical model of pancreatic cancer, when used in…
Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer
Posted: 29 May 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed…
PAT-DX1 draft GLP toxicology reports received
Posted: 29 May 2023 Patrys Limited, a therapeutic antibody development company, is pleased to announce that it has received favourable draft reports for two recently completed Good Laboratory Practice (GLP) toxicology studies testing PAT-DX1 in rats and a…
Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
Posted: 29 May 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new encouraging clinical data in 1st line non-small cell lung cancer from INSIGHT-003, an investigator-initiated Phase I…
Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership
Posted: 29 May 2023 Ginkgo’s ongoing partnership with Centrient focuses on improving the sustainability of fermentation and enzymatic syntheses of beta-lactam antibiotic APIs. In the first phase of this project, Ginkgo delivered an enzyme with significantly improved efficiency,…
4DMedical unveils VQ product at premier US lung conference
Posted: 24 May 2023 Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces a significant technological breakthrough and milestone in its product development strategy, with its CT-based ventilation-perfusion product (CT:VQ) progressing to a developmental…
Avecho enters strategic partnership with Arthur Group, licensing TPM for development of enhanced cancer drugs
Posted: 23 May 2023 Avecho Biotechnology Limited has today announced it has secured a licensing and development agreement with Arthur Group, entering a strategic partnership for the development of a series of cancer drugs solubilised using TPM®. Avecho…
Study results show new Sofra drug reduces inflammation
Posted: 23 May 2023 Innovative biotech company Noxopharm Limited announces a new preclinical product candidate from its Sofra™ technology platform has shown effectiveness against inflammatory skin disease in preclinical models. In research presented at the 15th International Congress…
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Posted: 23 May 2023 Immutep Limited a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that efti, a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co.,…
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
Posted: 23 May 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the US Food and Drug Administration (FDA), regarding the Company’s late-stage…
Artificial Intelligence powers second-skin-like wearable tech
Posted: 23 May 2023 A new ultra-thin skinpatch with nanotechnology able to monitor 11 human health signals has been developed by researchers at Monash University. Researchers from the Faculty of Engineering and Faculty of Information Technology combined nanotechnology…
New Centre for Advanced Defence Research and Enterprise established
Posted: 23 May 2023 A Centre for Advanced Defence Research and Enterprise (CADRE-OCE) to develop new concepts and technologies to protect Defence personnel, first responders and the general community has been launched at the University of Melbourne. The…
